Norethisterone Enanthate

• CAT Number: R032901
• CAS Number: 3836-23-5
• Molecular Formula: C27H38O3
• Molecular Weight: 410.598
• Purity: ≥95%
• Synonyms: 17-Hydroxy-19-Nor-17α-pregn-4-en-20-yn-3-one Heptanoate; 17α-Ethynyl-19-nortestosterone 17-Heptanoate; 17α-Ethynyl-19-nortestosterone Enanthate; NSC 22846; Norethindrone Enanthate; Norethisterone Heptanoate; Norigest; Noristerat; SH 8.0393; ZK 5410
• Target: Progesterone Receptor
• Storage: Store at room temperature
• IUPAC Name: [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
• InChI: InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1
• InChIKey: APTGJECXMIKIET-WOSSHHRXSA-N
• SMILES: CCCCCCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C

Norethisterone enanthate (NET-EN), also known as norethindrone enanthate, is a form of progestogen-only injectable birth control. It may be used following childbirth, miscarriage, or abortion. The failure rate per year is 2 per 100 women. Each dose lasts two months with up to two doses recommended.
Side effects may include breast pain, headaches, depression, irregular menstrual periods, and pain at the site of injection. Use in those with liver disease or during pregnancy is not recommended. Use appears to be okay during breastfeeding. It does not protect against sexually transmitted infections. Norethisterone enanthate is an ester of norethisterone, by which it works. It works by stopping ovulation.

Reference

1: Wistuba J, Nieschlag E, Semjonow A, Sandhowe-Klaverkamp R, Friderichs-Gromoll
S, Zitzmann M, Simoni M, Luetjens CM. Testosterone-induced prostate growth is
blocked by co- and preadministration of norethisterone enanthate in castrated
cynomolgus monkeys. Urol Int. 2012;88(3):358-64. doi: 10.1159/000335209. Epub
2012 Mar 8. PubMed PMID: 22414928.
2: Beksinska ME, Smit JA, Kleinschmidt I, Farley TM. Assessing menopausal status
in women aged 40 – 49 using depot-medroxyprogesterone acetate, norethisterone
enanthate or combined oral contraception. S Afr Med J. 2011 Feb;101(2):131-5.
PubMed PMID: 21678742.
3: Pelusi C, Costantino A, Cerpolini S, Pelusi G, Meriggiola MC, Pasquali R. A
placebo-controlled, randomized clinical trial using testosterone undecanoate with
injectable norethisterone enanthate: effect on anthropometric, metabolic and
biochemical parameters. Int J Androl. 2011 Dec;34(6 Pt 1):548-55. doi:
10.1111/j.1365-2605.2010.01122.x. Epub 2010 Nov 19. PubMed PMID: 21087288.
4: Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in a
cohort of adolescents during use of norethisterone enanthate,
depot-medroxyprogesterone acetate or combined oral contraceptives and after
discontinuation of norethisterone enanthate. Contraception. 2009 May;79(5):345-9.
doi: 10.1016/j.contraception.2008.11.009. Epub 2009 Jan 17. PubMed PMID:
19341845; PubMed Central PMCID: PMC3833049.
5: Molina RC, Sandoval JZ, Montero AV, Oyarzún PG, Molina TG, González EA.
Comparative performance of a combined injectable contraceptive (50 mg
norethisterone enanthate plus 5mg estradiol valerate) and a combined oral
contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in
adolescents. J Pediatr Adolesc Gynecol. 2009 Feb;22(1):25-31. doi:
10.1016/j.jpag.2008.07.010. PubMed PMID: 19232299.
6: Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in
adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or
combined oral contraceptives for contraception. Contraception. 2007
Jun;75(6):438-43. Epub 2007 Apr 5. PubMed PMID: 17519149.
7: Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G,
Christensen PD, Hull L, Swerdloff RS, Wang C. Pharmacokinetics of testosterone
undecanoate injected alone or in combination with norethisterone enanthate in
healthy men. J Androl. 2006 Nov-Dec;27(6):853-67. Epub 2006 Jul 12. PubMed PMID:
16837736.